India · Delayed Price · Currency is INR Orchid Pharma Statistics
Total Valuation
Orchid Pharma has a market cap or net worth of INR 49.66 billion. The enterprise value is 52.45 billion.
| Market Cap | 49.66B |
| Enterprise Value | 52.45B |
Important Dates
The last earnings date was Monday, May 25, 2026.
| Earnings Date | May 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 50.72M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 24.36% |
| Float | 15.30M |
Valuation Ratios
The trailing PE ratio is 241.67 and the forward PE ratio is 28.58.
| PE Ratio | 241.67 |
| Forward PE | 28.58 |
| PS Ratio | 6.12 |
| PB Ratio | 3.86 |
| P/TBV Ratio | 4.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 49.07 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 255.27 |
| EV / Sales | 6.46 |
| EV / EBITDA | 129.61 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.45 |
| Quick Ratio | 1.25 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 8.82 |
| Debt / FCF | -1.28 |
| Interest Coverage | 0.43 |
Financial Efficiency
Return on equity (ROE) is 1.61% and return on invested capital (ROIC) is 0.38%.
| Return on Equity (ROE) | 1.61% |
| Return on Assets (ROA) | 0.20% |
| Return on Invested Capital (ROIC) | 0.38% |
| Return on Capital Employed (ROCE) | 0.35% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 11.02M |
| Profits Per Employee | 279,171 |
| Employee Count | 736 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 1.80 |
Taxes
| Income Tax | -1.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.13% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +42.13% |
| 50-Day Moving Average | 719.56 |
| 200-Day Moving Average | 715.63 |
| Relative Strength Index (RSI) | 73.35 |
| Average Volume (20 Days) | 12,185 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orchid Pharma had revenue of INR 8.11 billion and earned 205.47 million in profits. Earnings per share was 4.05.
| Revenue | 8.11B |
| Gross Profit | 2.85B |
| Operating Income | 56.76M |
| Pretax Income | 203.55M |
| Net Income | 205.47M |
| EBITDA | 411.28M |
| EBIT | 56.76M |
| Earnings Per Share (EPS) | 4.05 |
Balance Sheet
The company has 832.11 million in cash and 3.63 billion in debt, with a net cash position of -2.79 billion.
| Cash & Cash Equivalents | 832.11M |
| Total Debt | 3.63B |
| Net Cash | -2.79B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 12.88B |
| Book Value Per Share | 253.98 |
| Working Capital | 4.05B |
Cash Flow
In the last 12 months, operating cash flow was 1.01 billion and capital expenditures -3.84 billion, giving a free cash flow of -2.82 billion.
| Operating Cash Flow | 1.01B |
| Capital Expenditures | -3.84B |
| Depreciation & Amortization | 354.53M |
| Net Borrowing | 1.72B |
| Free Cash Flow | -2.82B |
| FCF Per Share | n/a |
Margins
Gross margin is 35.18%, with operating and profit margins of 0.70% and 2.53%.
| Gross Margin | 35.18% |
| Operating Margin | 0.70% |
| Pretax Margin | 2.51% |
| Profit Margin | 2.53% |
| EBITDA Margin | 5.07% |
| EBIT Margin | 0.70% |
| FCF Margin | n/a |
Dividends & Yields
Orchid Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.03% |
| Shareholder Yield | -0.03% |
| Earnings Yield | 0.41% |
| FCF Yield | -5.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Orchid Pharma is 976.00, which is -0.60% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | 976.00 |
| Price Target Difference | -0.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |